Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more
Biotest Aktiengesellschaft (BIESF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.114x
Based on the latest financial reports, Biotest Aktiengesellschaft (BIESF) has a cash flow conversion efficiency ratio of -0.114x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.10 Million) by net assets ($509.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biotest Aktiengesellschaft - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biotest Aktiengesellschaft Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotest Aktiengesellschaft ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Collins Foods Limited
PINK:CLLFF
|
0.248x |
|
Edifier Technology Co Ltd
SHE:002351
|
0.053x |
|
Shanghai SK Automation Technology Co. Ltd. A
SHG:688155
|
N/A |
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
0.057x |
|
ABCELLERA BIOLOGICS
F:8QQ
|
N/A |
|
Cyfrowy Polsat S.A
OTCGREY:CYFWF
|
0.052x |
|
Weis Markets Inc
NYSE:WMK
|
0.044x |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
0.011x |
Annual Cash Flow Conversion Efficiency for Biotest Aktiengesellschaft (2002–2024)
The table below shows the annual cash flow conversion efficiency of Biotest Aktiengesellschaft from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $530.70 Million | $60.90 Million | 0.115x | +2220.40% |
| 2023-12-31 | $498.90 Million | $-2.70 Million | -0.005x | +95.04% |
| 2022-12-31 | $371.10 Million | $-40.50 Million | -0.109x | -222.46% |
| 2021-12-31 | $380.40 Million | $33.90 Million | 0.089x | +335.65% |
| 2020-12-31 | $441.60 Million | $-16.70 Million | -0.038x | +46.32% |
| 2019-12-31 | $476.90 Million | $-33.60 Million | -0.070x | +30.22% |
| 2018-12-31 | $495.20 Million | $-50.00 Million | -0.101x | -202.38% |
| 2017-12-31 | $347.80 Million | $34.30 Million | 0.099x | -46.02% |
| 2016-12-31 | $360.70 Million | $65.90 Million | 0.183x | +97.71% |
| 2015-12-31 | $412.30 Million | $38.10 Million | 0.092x | +489.25% |
| 2014-12-31 | $480.20 Million | $-11.40 Million | -0.024x | -51.90% |
| 2013-12-31 | $460.70 Million | $-7.20 Million | -0.016x | -116.63% |
| 2012-12-31 | $369.43 Million | $34.73 Million | 0.094x | -54.92% |
| 2011-12-31 | $346.67 Million | $72.28 Million | 0.208x | -17.59% |
| 2010-12-31 | $307.61 Million | $77.83 Million | 0.253x | +115.51% |
| 2009-12-31 | $269.86 Million | $31.68 Million | 0.117x | -13.75% |
| 2008-12-31 | $253.37 Million | $34.49 Million | 0.136x | -5.47% |
| 2007-12-31 | $225.76 Million | $32.51 Million | 0.144x | -38.53% |
| 2004-12-31 | $107.97 Million | $25.29 Million | 0.234x | +46.49% |
| 2003-12-31 | $103.29 Million | $16.52 Million | 0.160x | +619.93% |
| 2002-12-31 | $110.79 Million | $2.46 Million | 0.022x | -- |